At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
tandutinib +1 moredrug
Likely dose
tandutinib 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating tandutinib and laboratory biomarker analysis for Clear Cell Renal Cell Carcinoma and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedDec 2006
Primary CompletionOct 2008
Study CompletionDec 2008
TodayJul 2026
First PostedDec 7, 2006
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.6 years ago
Interventions
tandutinibdrug
Given orally, 500 mg bid daily
laboratory biomarker analysisother
Correlative studies